Success Metrics

Clinical Success Rate
84.4%

Based on 38 completed trials

Completion Rate
84%(38/45)
Active Trials
2(4%)
Results Posted
45%(17 trials)
Terminated
7(14%)

Phase Distribution

Ph not_applicable
7
14%
Ph phase_2
11
22%
Ph phase_3
9
18%
Ph phase_4
15
29%
Ph phase_1
6
12%

Phase Distribution

6

Early Stage

11

Mid Stage

24

Late Stage

Phase Distribution48 total trials
Phase 1Safety & dosage
6(12.5%)
Phase 2Efficacy & side effects
11(22.9%)
Phase 3Large-scale testing
9(18.8%)
Phase 4Post-market surveillance
15(31.3%)
N/ANon-phased studies
7(14.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.6%

38 of 46 finished

Non-Completion Rate

17.4%

8 ended early

Currently Active

2

trials recruiting

Total Trials

51

all time

Status Distribution
Active(2)
Completed(38)
Terminated(8)
Other(3)

Detailed Status

Completed38
Terminated7
unknown3
Recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
51
Active
2
Success Rate
84.4%
Most Advanced
Phase 4

Trials by Phase

Phase 16 (12.5%)
Phase 211 (22.9%)
Phase 39 (18.8%)
Phase 415 (31.3%)
N/A7 (14.6%)

Trials by Status

completed3875%
withdrawn12%
terminated714%
recruiting24%
unknown36%

Recent Activity

Clinical Trials (51)

Showing 20 of 51 trialsScroll for more
NCT04769206Phase 1

Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans

Recruiting
NCT01508494Phase 2

Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment

Completed
NCT07003386Phase 2

Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke

Recruiting
NCT03384784Phase 2

Effect of Galantamine on Inflammation and Cognition

Completed
NCT01100775Phase 2

Effects of Galantamine on Cognition

Completed
NCT00161044Not Applicable

An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms

Completed
NCT01012167Phase 2

Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia

Completed
NCT00606801Not Applicable

Galantamine Effects on Cognitive Function in Abstinent Cocaine Users

Completed
NCT00176423Phase 4

Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia

Completed
NCT02365285Phase 1

Racial Differences in Vagal Control of Glucose Homeostasis

Completed
NCT01669538Phase 2

Effect of Galantamine on Short-term Abstinence

Completed
NCT00809835Phase 2

Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse

Completed
NCT01531153Not Applicable

Cognitive Enhancement as a Target for Cocaine Pharmacotherapy

Completed
NCT03014323Phase 1

Racial Differences in Vagal Control of Glucose Homeostasis, Chronic Study

Withdrawn
NCT00509067Phase 2

Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia

Completed
NCT02374567Phase 3

Pharmacovigilance in Gerontopsychiatric Patients

Terminated
NCT00227994Phase 4

Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke

Completed
NCT01677754Phase 2

A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy

Completed
NCT01194336

Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance

Completed
NCT00195845Phase 4

A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder

Completed

Drug Details

Intervention Type
DRUG
Total Trials
51